Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose radiolabeled PK, metabolism, and excretion study of UCB1332 metabolites UCB0599 and UCB2713
NL-OMON43504Active, not recruiting
- Sponsor
- UCB
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of UCB1332 + NTP200-11, minzasolmin and UCB2713 in Parkinson's disease (PD) (4 arms), sponsored by UCB. Primary endpoints: Excretion balance of radiolabeled UCB0599 and UCB2713 after oral administration and Plasma and CSF pharmacokinetics of UCB0599 and UCB2713 and desmethyl metabolites. Started Nov 2015; status: active, not recruiting.
02
Drugs
UCB1332 + NTP200-11minzasolminUCB2713
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON43504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43504.